A quick peek into the report
Table of Contents
1.1Introduction
1.2Market Trends
1.3Regulatory Framework
1.4Pertussis: An Epidemiological Overview
1.5Clinical Development
1.6Market Dynamics
1.6.1Impact Analysis
1.6.2Market Drivers
1.6.3Market Challenges
1.6.4Market Opportunitie
2.1North America
2.1.1Key Findings
2.1.2Market Dynamics
2.1.3Market Sizing and Forecast
2.1.3.1North America Pertussis Market, by Country
2.1.3.1.1U.S.
2.2Europe
2.2.1Key Findings
2.2.2Market Dynamics
2.2.3Market Sizing and Forecast
2.2.3.1Europe Pertussis Market, by Country
2.2.3.1.1Germany
2.2.3.1.2U.K.
2.2.3.1.3France
2.2.3.1.4Italy
2.2.3.1.5Spain
2.3Asia Pacific
2.3.1Key Findings
2.3.2Market Dynamics
2.3.3Market Sizing and Forecast
2.3.3.1Asia Pacific Pertussis Market, by Country
2.3.3.1.1Japan
3.1Key Development Strategies
3.1.1Mergers and Acquisitions
3.1.2Synergistic Activities
3.1.3Business Expansions and Funding
3.1.4Product Launches and Approvals
3.1.5Other Activities
3.2Company Profiles
3.2.1GlaxoSmithKline Plc.
3.2.1.1Overview
3.2.1.2Top Products / Product Portfolio
3.2.1.3Top Competitors
3.2.1.4Target Customers/End-Users
3.2.1.5Key Personnel
3.2.1.6Analyst View
3.2.2Mitsubishi Tanabe Pharma
3.2.2.1Overview
3.2.2.2Top Products / Product Portfolio
3.2.2.3Top Competitors
3.2.2.4Target Customers/End-Users
3.2.2.5Key Personnel
3.2.2.6Analyst View
3.2.3Sanofi
3.2.3.1Overview
3.2.3.2Top Products / Product Portfolio
3.2.3.3Top Competitors
3.2.3.4Target Customers/End-Users
3.2.3.5Key Personnel
3.2.3.6Analyst View
3.2.4Sun Pharmaceutical Industries Ltd.
3.2.4.1Overview
3.2.4.2Top Products / Product Portfolio
3.2.4.3Top Competitors
3.2.4.4Target Customers/End-Users
3.2.4.5Key Personnel
3.2.4.6Analyst View
3.2.5ILiAD Biotechnologies.
3.2.5.1Overview
3.2.5.2Top Products / Product Portfolio
3.2.5.3Top Competitors
3.2.5.4Target Customers/End-Users
3.2.5.5Key Personnel
3.2.5.6Analyst View
4.Research Methodology
Table:Global Pertussis Market, Pricing Analysis,
Table:Global Pertussis Market Dynamics, Impact Analysis
Table:Global Pertussis Market, Clinical Trials Analysis
Table:Global Pertussis Market (by Region), $Million, 2023-2035
Figure:Global Pertussis Market, Market Overview
Figure:Global Pertussis Market, Epidemiological Analysis
Figure:Global Pertussis Market, Dynamics Impact Analysis
Figure:Global Pertussis Market Coverage
Figure:Global Pertussis Market Key Trends, Impact Analysis, 2023-2035
Figure:Global Pertussis Market, Competitive Landscape, January 2022-April 2025
Global Pertussis Report Coverage
Global Pertussis Market |
|||
Market Size in 2024 |
$XX Million |
Value Projection and Estimation by 2035 |
$XX Million |
Forecast Period |
2025-2035 |
Approx. CAGR During Forecast Period |
$XX Million |
Key Players
the market is benefiting from the support of international organizations such as the World Health Organization (WHO) and UNICEF, which are focused on enhancing immunization coverage globally, particularly in regions with lower vaccination rates. Government-funded programs and public-private partnerships are driving vaccine accessibility, especially in emerging markets.
Leading players in the global pertussis market, such as
Sanofi
GlaxoSmithKline Plc.
Sun Pharmaceutical Industries
and many others
How can this report add value to this organization ?
Product/Innovation Strategy: This report provides a comprehensive product/innovation strategy for the Global Pertussis Market , identifying opportunities for market entry, technology adoption, and sustainable growth. It offers actionable insights, helping organizations to meet environmental standards, gain a competitive edge, and capitalize on the increasing demand for eco-friendly solutions in various industries.
Growth/Marketing Strategy: This report offers a comprehensive growth and marketing strategy designed specifically for the Global Pertussis Market . It presents a targeted approach to identifying specialized market segments, establishing a competitive advantage, and implementing creative marketing initiatives aimed at optimizing market share and financial performance. By harnessing these strategic recommendations, organizations can elevate their market presence, seize emerging prospects, and efficiently propel revenue expansion.
Competitive Strategy: This report crafts a strong competitive strategy tailored to the Global Pertussis Market . It evaluates market rivals, suggests methods to stand out, and offers guidance for maintaining a competitive edge. By adhering to these strategic directives, companies can position themselves effectively in the face of market competition, ensuring sustained prosperity and profitability.
Introduction to Global Pertussis
Pertussis, commonly known as whooping cough, is a highly contagious respiratory infection caused by the bacterium Bordetella pertussis. It poses significant risks, particularly to infants and unvaccinated populations, with severe complications such as pneumonia, seizures, and even death. The global pertussis market focuses on prevention through vaccination, early diagnosis using several methods such as culture, digital polymerase chain reaction (PCR), paired sera, and single sera for effective treatment to mitigate its public health burden.
The global pertussis market includes various vaccine formulations such as whole-cell vaccines and acellular vaccines, which are used in pediatric and adult immunization schedules. These vaccines are being continually improved for safety, efficacy, and patient acceptance. Acellular vaccines, in particular, are gaining popularity due to their reduced side effects compared to whole-cell vaccines, driving the preference for these modern formulations.
As the global focus on vaccination intensifies, the pertussis market is evolving to meet the growing demand for more effective, longer-lasting, and easier-to-administer vaccine options. The market is influenced by factors such as increasing vaccination coverage rates, healthcare infrastructure improvements, rising healthcare awareness, and government initiatives promoting pertussis immunization programs.
A major driver for the pertussis market is the increasing awareness about the importance of vaccinating infants and pregnant women, particularly due to the high risk of severe complications for neonates. Maternal immunization programs, where pregnant women are vaccinated to protect their newborns, are seeing growing adoption. Moreover, the rising incidence of pertussis in older age groups, especially adolescents and adults, is prompting health authorities to recommend booster doses to prevent the spread of the disease.
Despite the positive market trends, there are challenges. Vaccine hesitancy in some regions, particularly in developed countries, and logistical barriers in low-income regions can hinder vaccination efforts. Additionally, maintaining vaccine coverage and addressing vaccine-related side effects remain important concerns. The cost of vaccines, especially for new formulations, and the complexity of vaccination schedules may also pose challenges for wider adoption.
Figure: Market Snapshot
Source: BIS Research Analysis
The competitive landscape of the global pertussis vaccine market is diverse, with numerous companies across different regions offering a variety of vaccine products. Regional players and local manufacturers are expected to play an increasingly important role in the market’s growth, particularly as vaccination coverage increases in emerging markets. As public health initiatives and government support for immunization programs grow, the pertussis market will continue to evolve, creating new opportunities for both established and emerging companies to expand their reach and cater to the rising demand for more effective and accessible treatment.
As the pertussis market continues to evolve, emerging trends such as the development of combination vaccines, advancements in acellular vaccine formulations, and the increasing adoption of maternal immunization programs are expected to significantly impact its future trajectory. The growing demand for more effective and safer vaccines, particularly those offering broader protection with fewer side effects, is driving innovation in vaccine development. Additionally, the rising number of pertussis cases, particularly in regions with low vaccination coverage, along with global efforts to improve vaccine accessibility, will present substantial opportunities for market growth, especially in developing regions with increasing healthcare investments.
In conclusion, the global pertussis market is poised for steady growth, driven by advancements in vaccine technology, increased immunization awareness, and global public health initiatives. As the demand for safer, more effective, and long-lasting vaccines rises, both established players and new entrants will play pivotal roles in addressing gaps in vaccine coverage and combating pertussis outbreaks. Ongoing research, the development of new vaccine formulations, and international collaborations will continue to reshape the market, ultimately reducing the global burden of pertussis and improving public health outcomes worldwide.
Pertussis Market - A Global and Regional Analysis
Focus on Regional and Country Analysis Analysis and Forecast
Frequently Asked Questions
The global pertussis market was valued at approximately $XX billion in 2023 and is projected to reach $XX billion by 2035, exhibiting a compound annual growth rate (CAGR) of approx. xx% from 2025 to 2035.
Major players in the global pertussis market include Sanofi., GlaxoSmithKline Plc., and Sun Pharmaceutical Industries Ltd. These companies lead the market by offering a range of innovative products designed for both healthcare institutions and individual consumers.
Driver:
· Rising prevalence of whooping cough
· Technological developments in vaccines
· High expenditure associated with pertussis medications